Imatinib is a small molecule commercialized by Aerovate Therapeutics, with a leading Phase III program in Pulmonary Arterial Hypertension. According to Globaldata, it is involved in 3 clinical trials, of which 1 was completed, and 2 are ongoing. GlobalData uses proprietary data and analytics to provide a complete picture of Imatinib’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.

The revenue for Imatinib is expected to reach an annual total of $405 mn by 2035 globally based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.

Imatinib Overview

Imatinib (AV-101) is under development for the treatment of pulmonary arterial hypertension (PAH). It is administered through the inhalational route as dry aerosol powder formulation. It acts by targeting Bcr-Abl tyrosine kinase, platelet derived growth factor receptor and mast/stem cell growth factor receptor kit.

Aerovate Therapeutics Overview

Aerovate Therapeutics is a biopharmaceutical company that focuses on developing treatments for rare cardiopulmonary diseases. It is headquartered in Boston, Massachusetts, the US.

The operating loss of the company was US$23 million in FY2021, compared to an operating loss of US$8.9 million in FY2020. The net loss of the company was US$23 million in FY2021, compared to a net loss of US$9.6 million in FY2020.

For a complete picture of Imatinib’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, drug margins and company expenses. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate valuation, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA) and phase transition success rate (PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.